OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo

OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.

OCTHF | IL

Overview

Corporate Details

ISIN(s):
GB00BMVMRB86
LEI:
2138005SRWT4998BCE35
Country:
United Kingdom
Address:
PRAMA HOUSE, 267 BANBURY ROAD, OX2 7HT OXFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

As of May 2025, Oxford Cannabinoid Technologies Holdings PLC has ceased trading and entered administration. Prior to this, the company operated as a clinical-stage biopharmaceutical firm engaged in the research, development, and commercialization of cannabinoid-based prescription medicines. The company focused on developing non-addictive therapies for the pain market, aiming to provide an alternative to opioids. Its drug discovery programs targeted the Endocannabinoid System (ECS) with a portfolio of proprietary derivatives, in-licensed compounds, and new chemical entities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-06-06 08:00
Delisting Announcement
Cancellation of Listing
English 10.0 KB
2024-05-31 08:00
Delisting Announcement
Updated Shareholder Engagement
English 10.6 KB
2024-05-17 17:30
Delisting Announcement
Updated Shareholder Information
English 22.6 KB
2024-05-08 08:00
Delisting Announcement
Intended Cancellation of Listing
English 32.1 KB
2024-04-11 12:26
Report Publication Announcement
Appointment of Phase I Clinical Trial CRO
English 17.3 KB
2024-04-03 09:00
Regulatory News Service
OCT Company Update with Doceo
English 7.4 KB
2024-03-26 11:56
Report Publication Announcement
Oxford Cannabinoid Technologies video with Doceo
English 6.9 KB
2024-03-18 08:00
Regulatory News Service
Appointment of Hybridan as Adviser
English 14.2 KB
2024-02-29 08:02
Board/Management Information
Directorate Appointment
English 15.3 KB
2024-02-29 08:01
Board/Management Information
Directorate Changes
English 16.2 KB
2024-02-29 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 11.8 KB
2024-02-28 18:35
Major Shareholding Notification
TR-1: NOTIFICATION OF MAJOR HOLDINGS
English 65.2 KB
2024-02-28 18:34
Major Shareholding Notification
TR-1: NOTIFICATION OF MAJOR HOLDINGS
English 71.7 KB
2024-02-28 18:34
Major Shareholding Notification
TR-1: NOTIFICATION OF MAJOR HOLDINGS
English 65.4 KB
2024-02-26 14:07
Director's Dealing
Directors’ Dealings
English 40.8 KB

Automate Your Workflow. Get a real-time feed of all OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea 225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea 314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea 228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea 066830
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway GENT
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea 358570
GlaxoSmithKline PLC Logo
A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.
United Kingdom GSK
GL Pharm Tech Corp. Logo
Develops improved drugs and generics, and licenses proprietary drug formulation technologies.
South Korea 204840
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan 2160

Talk to a Data Expert

Have a question? We'll get back to you promptly.